FY2025 EPS Estimates for Genmab A/S Decreased by Analyst

Genmab A/S (NASDAQ:GMAB) – Stock analysts at William Blair lowered their FY2025 EPS estimates for shares of Genmab A/S in a report issued on Tuesday, January 21st. William Blair analyst M. Phipps now forecasts that the company will post earnings per share of $1.38 for the year, down from their prior estimate of $1.60. The consensus estimate for Genmab A/S’s current full-year earnings is $1.28 per share.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. The company had revenue of $816.10 million for the quarter, compared to analyst estimates of $838.20 million. During the same quarter last year, the business earned $0.47 earnings per share.

A number of other equities research analysts also recently weighed in on GMAB. BMO Capital Markets reissued an “outperform” rating and set a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. Redburn Atlantic assumed coverage on shares of Genmab A/S in a research report on Tuesday, October 8th. They set a “buy” rating on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research report on Thursday. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Genmab A/S has a consensus rating of “Moderate Buy” and a consensus price target of $45.20.

Genmab A/S Price Performance

GMAB opened at $21.29 on Thursday. The business has a fifty day simple moving average of $21.07 and a 200 day simple moving average of $23.98. Genmab A/S has a 1 year low of $19.85 and a 1 year high of $31.88. The company has a market capitalization of $14.09 billion, a PE ratio of 20.67, a price-to-earnings-growth ratio of 0.59 and a beta of 0.97.

Institutional Trading of Genmab A/S

Several large investors have recently made changes to their positions in GMAB. Two Sigma Advisers LP lifted its stake in Genmab A/S by 84.1% during the third quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock worth $14,996,000 after purchasing an additional 280,900 shares during the last quarter. Cubist Systematic Strategies LLC raised its holdings in shares of Genmab A/S by 109.7% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock worth $7,000,000 after buying an additional 145,689 shares in the last quarter. FMR LLC lifted its position in shares of Genmab A/S by 13.5% during the 3rd quarter. FMR LLC now owns 278,194 shares of the company’s stock worth $6,782,000 after buying an additional 33,076 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its stake in Genmab A/S by 6.5% in the third quarter. Oppenheimer Asset Management Inc. now owns 232,243 shares of the company’s stock valued at $5,662,000 after buying an additional 14,165 shares in the last quarter. Finally, Natixis Advisors LLC grew its position in Genmab A/S by 29.8% in the third quarter. Natixis Advisors LLC now owns 206,563 shares of the company’s stock valued at $5,036,000 after acquiring an additional 47,437 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.